USD10
CRVS Shares
About Corvus PharmaceuticalsCorvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
USD10
CRVS Shares
About Corvus PharmaceuticalsCorvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.13B
OPEN PRICE
$14.11
LOW (1Y)
$2.54
HIGH (1Y)
$26.95
LOW (24H)
$12.95
HIGH (24H)
$14.40
VOLUME (24H)
$4.93M
299.54%
Price history
Time | Price | Change |
|---|---|---|
Today | $14.11 | |
1 Day | $13.33 | |
1 Week | $15.32 |